Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer.

MLA

Li, Siwei, et al. “Pirfenidone Inhibits CCL2-Mediated Treg Chemotaxis Induced by Palbociclib and Fulvestrant in HR+/HER2- Breast Cancer.” International Immunopharmacology, vol. 142, no. Pt A, Dec. 2024, p. 113059. EBSCOhost, https://doi.org/10.1016/j.intimp.2024.113059.

APA

Li, S., Zhang, X., & Pang, D. (2024). Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer. International Immunopharmacology, 142(Pt A), 113059. https://doi.org/10.1016/j.intimp.2024.113059

Chicago

Li, Siwei, Xianyu Zhang, and Da Pang. 2024. “Pirfenidone Inhibits CCL2-Mediated Treg Chemotaxis Induced by Palbociclib and Fulvestrant in HR+/HER2- Breast Cancer.” International Immunopharmacology 142 (Pt A): 113059. doi:10.1016/j.intimp.2024.113059.